Given the challenges associated with exhaustive surveillance programs, particularly in high-risk populations requiring frequent colonoscopies, targeting the cGAS-STING pathway could provide an adjunctive approach to reduce the burden of CRC risk. The gene discussed is STING1; the disease is colorectal carcinoma.